Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms

The discovery of JAK2/MPL mutations in patients with myeloproliferative neoplasms (MPN) led to clinical development of Janus kinase (JAK) inhibitors for treatment of MPN. These inhibitors improve constitutional symptoms and splenomegaly but do not significantly reduce mutant allele burden in patient...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bhagwat, Neha, Koppikar, Priya, Keller, Matthew, Marubayashi, Sachie, Shank, Kaitlyn, Rampal, Raajit, Qi, Jun, Kleppe, Maria, Patel, Hardik J., Shah, Smit K., Taldone, Tony, Bradner, James E., Chiosis, Gabriela, Levine, Ross L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Myeloid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3968390/
https://ncbi.nlm.nih.gov/pubmed/24470592
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2014-01-547760
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados